Bright Green is not profitable but is still a pre-revenue company. That could be changing. The company is projecting its latest move will eventually lead to $500 million in revenue.

One of the more unusual stocks in the unusual industry of marijuana, Bright Green (NASDAQ: BGXX), was quite the outlier on Thursday. In contrast to the sluggish performance of other weedies ...

Bright Green Corporation BGXX recently announced that it has successfully registered its federal license with the DEA for the cultivation, manufacture and sale of cannabis and cannabis-related ...

Bright Green press release (NASDAQ: BGXX): Q2 GAAP EPS of -$0.02. As of June 30, 2023, the Company had cash of $507,445, consistent with its cash position of $414,574 at December 31, 2022.

Bright Green (BGXX) stock shot up 200% Wednesday after the cannabis producer said it planned to raise $500M through the US government's EB-5 investment program. Read more here.

Bright Green, the first publicly traded company in the U.S. to be federally authorized to grow, manufacture and sell cannabis and cannabis-related products for research, pharmaceutical and medical ...

Achieving this substantial approval allows Bright Green to bring their deep expertise to these issues to help propel our Drugs Made in America movement forward.

Gurvinder Singh, also known as Groovy, the chief executive of Bright Green, expects to secure $15 million to plant the company’s first crop of cannabis and poppies inside green houses.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bright Green Corporati ...

Bright Green Corporation aims to disrupt the cannabis industry with its unique position and innovative strategies.

It will then receive a six-month option to buy the remainder of the company for an additional $6 million, plus $40 million worth of Bright Green stock.